BALTIMORE, May 16, 2016 – Elixirgen, LLC, announced today that it has entered into a worldwide exclusive license agreement with Keio University in Tokyo.
The agreement gives Elixirgen exclusive access to several key technologies developed at Keio University that allow for the efficient differentiation of human pluripotent stem cells into a variety of usable cell types, such as skeletal muscles and neurons.
Dr. Minoru Ko, Elixirgen’s co-founder and chief scientific officer, is a co-inventor of the technologies through his work at the Department of Systems Medicine at the Keio University School of Medicine. The technologies allow for the creation of rapid and scalable generations of functionally mature and relatively homogenous differentiated cells, which can be used for drug screening to identify therapeutic compounds, disease modeling to further study molecular mechanisms underlying the diseases, and cell replacement therapy in regenerative medicine.
Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as treatments for cell rejuvenation. Elixirgen is focused on curing humanity’s ailments through stem cell biology.
About Keio University:
Keio University is a private, higher education institution located in the Greater Tokyo area. It offers an environment of academic and research excellence, and includes a university hospital. Founded in 1858, it is Japan’s first modern institution of higher learning, and over the last century and a half it has established itself as a leader in Japan through its continued commitment to education, research and medicine. Additional information about Keio University is available at www.keio.ac.jp.